UK HTA (health technology assessment) body unimpressed by clinically-effective but "expensive" Exubera inhaled insulin from Pfizer
This article was originally published in Clinica
Executive Summary
Inhaled insulin was today given a provisional thumbs down in the ongoing appraisal of its potential use to treat type 1 and 2 diabetes in the UK's National Health Service, on the basis of its cost. The health technology assessment (HTA) conducted for the National Institute for Health and Clinical Excellence (NICE) is based on a review of Exubera, manufactured by Pfizer. The delivery device is produced by Bespak in the UK and West Pharmaceuticals in the US.